Premium
Patient satisfaction with an injection device for multiple sclerosis treatment
Author(s) -
Cramer J. A.,
Cuffel B. J.,
Divan V.,
AlSabbagh A.,
Glassman M.
Publication year - 2006
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2005.00568.x
Subject(s) - multiple sclerosis , medicine , patient satisfaction , physical therapy , surgery , psychiatry
Objectives – To develop a measure of treatment satisfaction assessing attributes specific to injected interferon‐beta‐1a (IFN‐ β ‐1a) for multiple sclerosis (MS), and to test pain and instrument sensitivity to change among patients changing injection devices. Materials and methods – The MS Treatment Concerns Questionnaire (MSTCQ) was developed and tested with pain assessments before and 3 months after patients changed devices from Rebiject to Rebiject II. Results – The MSTCQ was organized with two domains: Injection System Satisfaction and Side Effects (three subscales: Injection Site Reactions, Global Satisfaction, and Flu‐Like Symptoms). Significant improvements ( P = 0.002 to P < 0.001) occurred with the new injection device in all MSTCQ subscales (except Flu‐Like Symptoms), and all pain measures ( P < 0.0001). Clinically meaningful improvement was demonstrated in all scales, except Flu‐Like Symptoms, by effect sizes (0.23–0.59). Conclusions – These statistically significant and clinically meaningful improvements in MSTCQ and pain measures show the value of technologically advanced devices in domains of concern to patients.